Komori
Business alliance4597Solasia Pharma K.K.Pharmaceuticals

(Correction) Partial Correction to “Notice of Additional Investment in Partner Company Isofol for Development Product SP-05”

The number of Isofol shares held by the Company and the Company’s ownership interest following the additional investment announced on 1 April 2026 have been corrected. The number of shares held has been revised from 8,333,328 to 10,416,660, and the ownership interest from 2.6% to 3.25%.

Worth reading
47Recurring
Scored from 2 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2083332
Shares (the ownership interest changed by 0.65 percentage points)
Wording
Definitive
How definitive the wording is.

The document this correction applies to

Timely disclosure
Notice of Additional Investment in Partner Company Isofol for Development Product SP-052026-04-01

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure1 April 2026

Notice of Additional Investment in Partner Company Isofol for Development Product SP-05

Open the original document
1 dayThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-04-02
Location of correction (where in the original document)

The number of Isofol shares held by the Company following the additional subscription and Isofol’s ownership interest held by the Company following the additional subscription

Before correction

Number of Isofol shares held by the Company following the additional subscription: 8,333,328 shares; Isofol’s ownership interest held by the Company following the additional subscription: 2.6%

After correction

Number of Isofol shares held by the Company following the additional subscription: 10,416,660 shares; Isofol’s ownership interest held by the Company following the additional subscription: 3.25%

Reason for correction

Certain information required correction.

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice of Additional Investment in Partner Company Isofol for Development Product SP-05
Original disclosure date1 April 2026
Location of correctionThe number of Isofol shares held by the Company following the additional subscription and Isofol’s ownership interest held by the Company following the additional subscription
Details of correctionNumber of Isofol shares held by the Company following the additional subscription: 8,333,328 shares; Isofol’s ownership interest held by the Company following the additional subscription: 2.6% → Number of Isofol shares held by the Company following the additional subscription: 10,416,660 shares; Isofol’s ownership interest held by the Company following the additional subscription: 3.25%
Reason for correctionCertain information required correction.
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Certain items in the disclosure required correction. The specific cause is not disclosed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial Correction to “Notice of Additional Investment in Partner Company Isofol for Development Product SP-05” | Solasia Pharma K.K. (4597) timely disclosure | Komori